|
FDA Guidance on Container Closure Systems (CCS) and Out of Specification Investigations (OOS)“The Mystery of the Disappearing Fentanyl” case study highlights the potential impact of the container closure system on a final drug product, and the importance of having a comprehensive and robust investigation process. To minimize issues associated with a specific CSS, a firm must go through a qualification process to determine the “Suitability” of a container closure system with their drug product. A CCS is deemed suitable only after… |
Container Closure System (CCS) Suitability ServicesA proactive and comprehensive strategy for qualifying and selecting CCS’s that are compatible and adequately protect your products is essential. Discovering that the active ingredient has an affinity to one of the components of the CCS, or the CCS does not protect the product from light, water, air or microbial intrusion, or causes the active to degrade, or has an extractable or leachable substance that is harmful to the patient or interferes with the testing methodology, is not something a firm wants to discover during an expensive and time consuming stability study, or just prior to launching product to the market. Whether you are at the beginning of the process of selecting a CCS, or you have a product in the market or that is ready to go to market, contact us today about our CQI Partner Program “Component Qualification” services. We will work with you to design a comprehensive and cost-effective program to qualify new and existing CCS’s. For more information, please contact us at sales@dynalabs.us to learn more about the program. |
|
DYNALABS is happy to announce:Recent Promotions of: The addition of John Weber as a Customer Support Specialist for our expanding National Accounts. John graduated with a Bachelor of Arts in Biology from University of Missouri – St. Louis. The addition of Jeremy Knutson as the Metrology Supervisor. Jeremy graduated with a Bachelor of Science degree in Chemistry from Bemidji State University in Bemidji, MN. |
|
||||||||
|